Seaport Therapeutics doses first patient in Phase 2a GAD trial
Share
- Seaport Therapeutics dosed the first patient in an Australian Phase 2a clinical trial evaluating GlyphAgo for generalized anxiety disorder.
- Following the clinical trial update, the company's share price traded lower at $24.80.
- The company expects to report topline data from the Phase 2a study in early 2028 before completing a broader Phase 2/3 trial by late 2028.
Seaport Therapeutics (NASDAQ:SPTX) dosed the first patient in its Phase 2a clinical trial in Australia evaluating GlyphAgo in adults with generalized anxiety disorder and sleep disturbance.
The clinical study evaluates two specific dose levels of the oral prodrug in patients with co-morbid sleep issues to establish proof-of-pharmacology.
"Despite the widespread impact of GAD, there have been no new approved therapies in almost two decades, and many patients continue to experience inadequate symptom relief or tolerability issues that limit treatment," said Seaport Therapeutics Chief Executive Officer Daphne Zohar.
The company designed the therapy with its proprietary Glyph platform to bypass first-pass liver metabolism and reduce potential hepatic risks.
The company expects to report topline data from the six-week Phase 2a trial in early 2028.
Seaport Therapeutics also plans to initiate a global Phase 2/3 trial in the first half of 2027 and expects topline data by the end of 2028.
